Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039377 | PMC |
| http://dx.doi.org/10.1038/msb.2013.64 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring Denosumab in the Treatment of Giant Cell Tumors: Clinical Evidence and Controversies.
J Craniofac Surg
November 2024
Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL.
Giant cell tumors (GCTs) are benign but locally aggressive bone neoplasms that primarily affect skeletally mature individuals. They are characterized by a tendency for recurrence and being associated with significant morbidity. Traditional treatment has focused on surgical resection; however, the role of medical therapies, such as Denosumab, a bone anti-resorptive drug, which has been Food and Drug Administration (FDA)-approved for unresectable GCTs since 2013, recently has gained prominence.
View Article and Find Full Text PDFGynura procumbensin vitro adventitious root nanohydrogel improves inflammation-proliferation transition in second-degree burn healing.
Braz J Biol
January 2025
Universitas Airlangga, Faculty of Science and Technology, Department of Biology, Mulyorejo, Surabaya, Indonesia.
Inflammation-proliferation transition plays a key role in the successful healing of a common burn type, second-degree burn. Gynura procumbens in vitro adventitious root nanohydrogel is currently being studied for its immunomodulatory to improve reparative environment. Root production and nanohydrogel preparation was done respectively by in vitro propagation and emulsion/ solvent diffusion with carbomer as a polymer.
View Article and Find Full Text PDFEpithelial OPA1 links mitochondrial fusion to inflammatory bowel disease.
Sci Transl Med
January 2025
Department of Medicine 1, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91052 Erlangen, Germany.
Dysregulation at the intestinal epithelial barrier is a driver of inflammatory bowel disease (IBD). However, the molecular mechanisms of barrier failure are not well understood. Here, we demonstrate dysregulated mitochondrial fusion in intestinal epithelial cells (IECs) of patients with IBD and show that impaired fusion is sufficient to drive chronic intestinal inflammation.
View Article and Find Full Text PDFIncreased Systemic Immune-Inflammatory Index and Association with Occult Nodal Disease in Non-Small Cell Lung Cancer.
J Am Coll Surg
November 2024
Department of Cardiovascular and Thoracic Surgery, Rush University Medical Center, Chicago, Illinois, USA.
Background: It has been proposed that more aggressive tumors trigger a stronger inflammatory response than less aggressive types. We hypothesize that systemic immune inflammatory index (SII) is associated with occult nodal disease (OND) in clinically node negative (cN0) patients undergoing lung resection for non-small cell lung cancer (NSCLC).
Study Design: The study included patients who underwent lung resection with nodal dissection, according to current guidelines, at a single center between 2010-2021 for NSCLC.
A novel broad-spectrum bacteriophage cocktail against methicillin-resistant Staphylococcus aureus: Isolation, characterization, and therapeutic potential in a mastitis mouse model.
PLoS One
January 2025
Department of Pharmaceutical Biotechnology and Biotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Bovine mastitis is a considerable challenge within the dairy industry, causing significant financial losses and threatening public health. The increased occurrence of methicillin-resistant Staphylococcus aureus (MRSA) has provoked difficulties in managing bovine mastitis. Bacteriophage therapy presents a novel treatment strategy to combat MRSA infections, emerging as a possible substitute for antibiotics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!